The abstract is read at the publisher; the summary is JClub's.
Dual EZH1/2 inhibition with DNMT inhibition more robustly activates transcription in colorectal cancer cells by depleting H3K27 methylation states and overcoming adaptive chromatin barriers.
- Why it matters: DNMT inhibitors can be constrained by PRC2-dependent epigenetic plasticity, limiting transcriptional responses in solid tumors and motivating better combination strategies.
- What they did: The study compared pharmacologic EZH1/2 targeting plus DNMT inhibition in colorectal cancer cells, using genetic and drug-based analyses to distinguish EZH2-selective versus dual EZH1/2 effects on chromatin states.
- The result: EZH1-dependent H3K27me1 acts as an adaptive barrier to PRC2 inhibitor-mediated remodeling, and dual EZH1/2 plus DNMT inhibition increases accessibility and H3K27ac while resolving a DNMT-maintained non-canonical bivalent repression state.
The findingWhy it mattersWhat they didThe result
AI summary of the abstract · may contain errors · not medical advice · read the paper.